Revolution Medicines Inc.... (RVMDW)
Company Description
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers.
The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.
Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets.
The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial.
Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
| Country | United States |
| IPO Date | n/a |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 534 |
| CEO | Dr. Mark A. Goldsmith Ph.D. |
Contact Details
Address: 700 Saginaw Drive Redwood City, United States | |
| Website | https://www.revmed.com |
Stock Details
| Ticker Symbol | n/a |
| Exchange | NASDAQ |
| Fiscal Year | n/a |
| Reporting Currency | USD |
| CIK Code | n/a |
| CUSIP Number | n/a |
| ISIN Number | n/a |
| Employer ID | - |
| SIC Code | n/a |
Key Executives
| Name | Position |
|---|---|
| Dr. Mark A. Goldsmith Ph.D. | Chief Executive Officer, President & Chairman |
| Jack Anders | Chief Financial Officer |
| Margaret A. Horn J.D. | Chief Operating Officer |
| Walter Reiher Ph.D. | Chief Information Officer |
| Dr. Kevan M. Shokat Ph.D. | Academic Co-Founder & Member of Scientific Advisory Board |
| Dr. Martin D. Burke M.D., Ph.D. | Co-Founder & Chairman of Scientific Advisory Board |
| Dr. Michael A. Fischbach Ph.D. | Academic Co-Founder & Member of Scientific Advisory Board |
| Dr. Stephen M. Kelsey FRC Path., FRCP, M.D. | President of Research & Development |
| Jan Smith Ph.D. | Chief Scientific Officer |
| Xiaolin Wang | Executive Vice President of Development |